Compare Novartis with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs UNICHEM LAB - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS UNICHEM LAB NOVARTIS/
UNICHEM LAB
 
P/E (TTM) x 910.4 -86.8 - View Chart
P/BV x 27.4 0.5 5,743.1% View Chart
Dividend Yield % 1.6 2.9 55.6%  

Financials

 NOVARTIS   UNICHEM LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-19
UNICHEM LAB
Mar-19
NOVARTIS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs980292 335.6%   
Low Rs600182 329.8%   
Sales per share (Unadj.) Rs198.7167.7 118.5%  
Earnings per share (Unadj.) Rs21.0-3.6 -577.5%  
Cash flow per share (Unadj.) Rs22.35.9 374.6%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.31.7 75.0%  
Book value per share (Unadj.) Rs307.5372.3 82.6%  
Shares outstanding (eoy) m24.6970.38 35.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.01.4 281.3%   
Avg P/E ratio x37.7-65.3 -57.7%  
P/CF ratio (eoy) x35.539.9 89.0%  
Price / Book Value ratio x2.60.6 403.6%  
Dividend payout %47.7-110.2 -43.3%   
Avg Mkt Cap Rs m19,50816,680 117.0%   
No. of employees `0000.62.6 22.3%   
Total wages/salary Rs m1,1712,393 48.9%   
Avg. sales/employee Rs Th8,445.44,535.2 186.2%   
Avg. wages/employee Rs Th2,015.7919.8 219.2%   
Avg. net profit/employee Rs Th891.0-98.2 -907.3%   
INCOME DATA
Net Sales Rs m4,90711,801 41.6%  
Other income Rs m783984 79.5%   
Total revenues Rs m5,68912,785 44.5%   
Gross profit Rs m123-835 -14.7%  
Depreciation Rs m32674 4.7%   
Interest Rs m1675 21.1%   
Profit before tax Rs m858-600 -143.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m340-343 -99.0%   
Profit after tax Rs m518-256 -202.6%  
Gross profit margin %2.5-7.1 -35.4%  
Effective tax rate %39.657.3 69.2%   
Net profit margin %10.6-2.2 -487.2%  
BALANCE SHEET DATA
Current assets Rs m8,05520,384 39.5%   
Current liabilities Rs m1,8505,029 36.8%   
Net working cap to sales %126.4130.1 97.2%  
Current ratio x4.44.1 107.4%  
Inventory Days Days45105 43.0%  
Debtors Days Days34135 25.1%  
Net fixed assets Rs m1509,023 1.7%   
Share capital Rs m123141 87.6%   
"Free" reserves Rs m7,46926,058 28.7%   
Net worth Rs m7,59226,199 29.0%   
Long term debt Rs m00-   
Total assets Rs m9,82431,496 31.2%  
Interest coverage x54.9-7.0 -787.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.4 133.3%   
Return on assets %5.4-0.6 -948.6%  
Return on equity %6.8-1.0 -699.2%  
Return on capital %11.5-2.0 -575.5%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m588,188 0.7%   
Fx outflow Rs m1,326596 222.5%   
Net fx Rs m-1,2697,592 -16.7%   
CASH FLOW
From Operations Rs m-1,943-3,278 59.3%  
From Investments Rs m2,742-2,860 -95.9%  
From Financial Activity Rs m-298-24 1,232.2%  
Net Cashflow Rs m501-4,690 -10.7%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 15.1 13.2%  
FIIs % 1.6 3.0 53.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 31.7 67.8%  
Shareholders   41,647 20,176 206.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 161 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower, tracking weakness in global markets owing to coronavirus outbreak.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 18, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS